Exploring Renal Malignancies in Saudi Arabia: Insights from a Tertiary Care Center Study
Main Article Content
Keywords
Kidney Cancer, Renal Cell Carcinoma, Clear Cell RCC, Chromophobe RCC, Papillary RCC
Abstract
This retrospective study aims to describe the characteristics of renal cell carcinoma (RCC) in Saudi Arabia, in terms of epidemiology, clinical presentation, tumor subtype, Fuhrman grade, tumor size and stage, and overall survival. A total of 431 adult patients with a histopathological diagnosis of RCC between 2015 and 2023 were included in the analysis. Most patients (72.4%) had clear cell tumors, followed by chromophobe (15.1%) and papillary (12.5%) subtypes. In males, papillary RCC (85.2%) was more common compared to clear cell (59.8%) and chromophobe (67.7%) subtypes. Significant differences were observed in median body mass index (BMI) across tumor subtypes, and papillary tumor patients exhibited the highest incidence of hematuria (33.3%) compared to other subtypes. The Fuhrman grade also varied significantly among RCC types. Survival times were found to be lower for patients with papillary tumors. No significant difference was observed based on patients’ nationality. This study can inform clinical decision-making on patient prognosis and management as well as public health efforts aimed at reducing the alarming rise of RCC incidence.
References
2. Alkhateeb SS, Alothman AS, Addar AM, Alqahtani RA, Mansi TM, Masuadi EM. Kidney cancer in Saudi Arabia. A 25-year analysis of epidemiology and risk factors in a tertiary center. Saudi Med J. 2018 May;39(5):459–463. 10.15537/smj.2018.5.22641
3. Abomelha MS. Trends of genitourinary cancer among Saudis. Arab J Urol. 2011;9(3):199–202. 10.1016/j.aju.2011.10.006
4. Capitanio U, Montorsi F. Renal cancer. The Lancet. 2016; 387(10021):894–906. 10.1016/S0140-6736(15)00046-X
5. Elhadd TA, Al-Amoudi AA, Alzahrani AS. Epidemiology, clinical and complications profile of diabetes in Saudi Arabia: a review. Annals of Saudi medicine. 2007;27(4):241–50. 10.5144/0256-4947.2007.241
6. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. New England Journal of Medicine. 2017;376(4):354–66. 10.1056/NEJMra1601333
7. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23(12):2763–71. 10.1200/JCO.2005.07.055
8. Cairns P. Renal cell carcinoma. Cancer Biomark. 2010; 9(1–6):461–73.
9. Mahasin SZ, Aloudah N, Al-Surimi K, Alkhateeb SS. Epidemiology profile of renal cell carcinoma: A 10-year patients’ experience at King Abdulaziz Medical City, National Guard Health Affairs, Saudi Arabia. Urol Ann. 2018;10(1):59–64. 10.4103/UA.UA_102_17
10. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27(5):612–24. 10.1097/00000478-200305000-00005
11. Teloken PE, Thompson RH, Tickoo SK, Cronin A, Savage C, Reuter VE, et al. Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol. 2009;182(5):2132–6. 10.1016/j.juro.2009.07.019
12. Alawad SA, Alghamdi MH, Alharbi MG, Addar A, Khayal AMA, Alasker A. Characteristics of renal cell carcinoma in Saudi patients below the age of 50 years. Urology Annals. 2022;14(1):15–20. 10.4103/ua.ua_14_21
13. Abu-Ghanem Y, Powles T, Capitanio U, Beisland C, Järvinen P, Stewart GD, et al. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium. Eur Urol Oncol. 2021;4(3):473–82. 10.1016/j.euo.2020.09.005
14. Ikuemonisan J, Togun A, Oyejinmi I, Bakare A, Adejoro O. Influence of Histologic Types and Subtypes on Survival Outcomes of Intermediate-High and High-Risk Renal Cell Carcinoma Following Nephrectomy: Findings From the SEER Database. Urology. 2022;159:146–51. 10.1016/j.urology.2021.08.034
15. Nguyen DP, Vertosick EA, Corradi RB, Vilaseca A, Benfante NE, Touijer KA, et al. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. Urologic Oncology: Seminars and Original Investigations. 2016;34(6):259.e1-.e8. 10.1016/j.urolonc.2016.01.005
16. Mai KT, Landry DC, Robertson SJ, Commons AS, Burns BF, Thijssen A, et al. A Comparative Study of Metastatic Renal Cell Carcinoma with Correlation to Subtype and Primary Tumor. Pathology-Research and Practice. 2001;197(10):671–5. 10.1078/0344-0338-00144
17. Rabjerg M, Gerke O, Engvad B, Marcussen N. Comparing World Health Organization/International Society of Urological Pathology Grading and Fuhrman Grading with the Prognostic Value of Nuclear Area in Patients with Renal Cell Carcinoma. Uro. 2021;1:2–13. 10.3390/uro1010002
18. Delahunt B, Eble JN, Egevad L, Samaratunga H. Grading of renal cell carcinoma. Histopathology. 2019;74(1):4–17. 10.1111/his.13735
19. Beck SDW, Patel MI, Snyder ME, Kattan MW, Motzer RJ, Reuter VE, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Annals of Surgical Oncology. 2004;11(1):71–7.
20. Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, et al. Histological Subtype is an Independent Predictor of Outcome for Patients With Renal Cell Carcinoma. The Journal of Urology. 2010;183(4):1309–16. 10.1016/j.juro.2009.12.035
21. Dudani S, de Velasco G, Wells JC, Gan CL, Donskov F, Porta C, et al. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. JAMA Network Open. 2021;4(1):e2021869-e. 10.1001/jamanetworkopen.2020.21869
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.